What’s new

• Revenue of ₹8.20 cr and net profit of ₹0.61 cr for June quarter
• Board proposes rename to Pasura Industries Limited, subject to shareholder approval
• Waived ₹25.19 lakh excess remuneration; raised three directors' salaries to ₹8 lakh and ₹5 lakh per month

Why it matters

For a nano-cap with ₹105 cr market cap and high debt, the sharp turnaround from loss to profit signals operational improvement. The rebranding hints at a strategic shift, but the salary hikes and waiver raise governance scrutiny. Sustaining profitability is the key test.

What we’re watching

• Shareholder vote on name change at 12 Aug 2026 AGM
• Q2 FY27 performance to confirm trend
• Debt reduction progress given 0.79 debt/equity ratio

The full read

Arunjyoti Bio Ventures has posted a sharp reversal. For the quarter ended June 2026, it reported a net profit of ₹0.61 crore on revenue of ₹8.20 crore, swinging from a loss in the March quarter. Total income rose to ₹8.22 crore while expenses fell, producing an operating profit of ₹0.82 crore. The board also proposed renaming the company to Pasura Industries Limited — a move that suggests a change in identity, perhaps beyond the bio-ventures label. But alongside that came a waiver of ₹25.19 lakh in excess managerial remuneration paid in FY26 and salary hikes for three directors to ₹8 lakh, ₹5 lakh and ₹5 lakh per month, each with ₹10 lakh travel allowance. For a nano-cap with ₹105 crore market cap and debt of 0.79 times equity, the profit is welcome but the governance optics are mixed. The next quarter will show whether the turnaround has legs. The AGM on 12 August 2026 will test shareholder sentiment on the name change and the pay packets.

Primary source: BSE · NSE